Physician profile
Daniel Yeoun
NPI 1245624121
$3,809.71
in general payments reported to CMS, 2019-2025
20 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $542 · 2023: $998 · 2024: $1,000 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,021 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,020.95 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $666.42 | 2022-2025 | Ibsrela |
| Abbvie INC. | $597.22 | 2022-2025 | Skyrizi, Mavyret, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $435.93 | 2022-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $373.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $314.08 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $249.27 | 2023-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $184.30 | 2021-2023 | |
| Janssen Biotech, INC. | $153.48 | 2022-2025 | Tremfya, Stelara, Remicade |
| Intra-Sana Laboratories | $151.75 | 2023-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $135.62 | 2024-2025 | Entyvio, Eohilia |
| Angiodynamics, INC. | $135.48 | 2024 | Angiodynamics |
| Merck Sharp & Dohme LLC | $109.10 | 2023-2024 | Dificid |
| Exact Sciences Corporation | $89.26 | 2023-2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $55.54 | 2022-2023 | Linzess |
| Celltrion USA INC. | $52.92 | 2025 | Vegzelma |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $36.78 | 2022-2025 | Talicia |
| Amgen INC. | $22.98 | 2024 | |
| Capsovision, INC. | $15.91 | 2023 | Capsocam Plus |
| Novo Nordisk INC | $15.84 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $14.57 | 2024 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Yeoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.